WO2006123765A1 - Film coated preparation - Google Patents

Film coated preparation

Info

Publication number
WO2006123765A1
WO2006123765A1 PCT/JP2006/309993 JP2006309993W WO2006123765A1 WO 2006123765 A1 WO2006123765 A1 WO 2006123765A1 JP 2006309993 W JP2006309993 W JP 2006309993W WO 2006123765 A1 WO2006123765 A1 WO 2006123765A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
film
formulation
coating formulation
film layer
coating
Prior art date
Application number
PCT/JP2006/309993
Other languages
French (fr)
Japanese (ja)
Inventor
Takeshi Hamaura
Susumu Hasegawa
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A film coated preparation which contains a smelling drug in its formulation and further contains sodium carboxymethylcellulose in the film layer thereof.

Description

Specification

Film co one coating formulation

Technical field

[0001] The present invention relates to a film coating formulation.

BACKGROUND

[0002] Some drugs, smell like recipient feels uncomfortable, and it is known that there is a drug with a formulation containing these, I and causing a reduction in the recipient's compliance Ri, and also affects the commercial value.

[0003] In the prior art, for example, a sugar-coated tablets, odor, to force sugar batter tablet was possible to mask the has a disadvantage that the tablets are not easily taken in size. Further, the coated film coated tablets with a film layer obtained by blending hydroxypropyl methylation cellulose

Although masking the unpleasant odor of the drug is known (JP 2003- 300883 Patent Gazette), the effect of the odor suppression was insufficient.

Patent Document 1: JP 2003- 300883 JP

Disclosure of the Invention

Problems that the Invention is to you'll solve

[0004] An object of the present invention is to provide a film coating formulation can reduce odor possessed by the drug, the.

Means for Solving the Problems

[0005] The present inventors have found as a result of intensive studies in order to achieve the above object, surprisingly, we found that can reduce the odor of the formulation and coated with a film layer obtained by blending sodium carboxymethylcellulose, completed the present invention It was.

[0006] Namely, the present invention is,

(1) a film coating formulation odor in the formulation! Contains agents having, containing carboxymethyl cell row scan sodium film layer,

(2) containing olmesartan medoxomil in the formulation, film coating formulation containing carboxymethyl cellulose sodium film layer, (3) simultaneously comprising olmesartan medoxomil and other drugs in the formulation, carboxymethylcellulose sodium film layer film coating formulations containing,

(4) in the formulation 2-Amino - 5-isobutyl -4- {2- [5- (Ν, Ν'- bis ((S)-l-ethoxycarbonyl - Le) Echiru) phosphonamido] Hula - Le} containing thiazole, film coating formulations containing carboxymethyl cellulose sodium film layer,

(5) to the film layer, the film coating formulation according to any one of (1) one (4) is further coating composition containing a coating base or excipient,

(6) coating bases or excipients force hydroxymethyl cellulose, hydrate Loki Cipro Pinot receptacle Honoré loin, polyvinylidine Honoré pyrrolidone, polyvinylidine Honoré Ano records Honoré, Mechinoresenore port over scan, E chill cellulose, dextrin, maltodextrin, lactose , D- Man - tall, port polyvinyl alcohol polymer, wherein methacrylic acid copolymer, aminoalkyl methacrylate copolyarylene Rimmer and one or more in which the above methyl acrylate Echiru 'methacrylate copolymer force chosen compound (5) of film coating formulation,

(7) a film coating formulation according to coating base or excipient force maltodextrin or dextrin in the above (5),

(8) in the film layer, further off Ilm coating formulation according to any one of (1) one (7) containing a plasticizer,

(9) a plasticizer force macrogol 6000, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin and sorbitol, glycerin triacetate, phthalic acid Jechiru and Taen acid triethyl, lauric acid, sucrose, dextrose, sorbitol, Toriasechin, Asechi Norre tri E Chino les Tito, tri E Chino les Tito rate, film coating formulation according to the is (8) one or more compounds selected tributyl Chino retinyl Torre one bets from § cetyl tributyl Tito rate,

(10) plasticizer, film coating formulation according to dextrose (8),

(11) plasticizer, film coating formulation according to a Toriasechin (8),

(12) formulation is a tablet (1) - film coating formulation according to any one of (11)

(13) Film layer forces l% relative formulation weight (w / w) or more in the above (1) i (12), whichever is the film coating formulations described,

(14) Film layer strength 3% relative formulation weight (w / w) or more in the above (1) i (12), whichever is the film coating formulations described,

(15) Film layer strength 6% relative to the formulation weight (w / w) or more in the above (1) i (12), whichever is the film coating formulations described,

(16) the thickness of the film layer, of 1 mu m or more in a claim (1) i (12), a film coating preparation according to any displacement,

(17) a film coating formulation according to any one of the film thickness force 5 m (16.4 feet) or more in a claim of the film layer (1) i (12),

(18) a film coating formulation according to any one of the film layer having a thickness of force 10 m or more in a claim (1) i (12),

(19) thickness force 20 m or more in a claim of the film layer (1) is to provide a film coating formulation, such as described in any one (12).

[0007]

Effect of the invention

[0008] According to the present invention, it is possible to provide an excellent film coating formulation substantially above smell!, The such ,, marketability.

BEST MODE FOR CARRYING OUT THE INVENTION

[0009] The present invention in film coating formulations Nio, Te contains carboxymethyl chill cellulose sodium (CMC-Na) in the film layer. Thus, the odor included in the drug can effectively reduce, and stable film coating formulation can be obtained over time. The content of the sodium carboxymethylcellulose Fi Lum layer, Do particularly limited as long as it is an amount capable of reducing odor agent has, effectively, but usually the lower limit is 20% (w / w) on more than , preferably 30% (w / w) or more, more preferably 40% (w / w) or more, the upper limit is less than 90% (w / w), preferably 80% (w / w ) or less, more preferably not more than 70% (w / w).

[0010] The film layer may be blended with other coating base or excipient as necessary. Type of coating base or excipient is not particularly limited, those skilled in the art may be appropriately selection. Such coating base or excipient, for example, Poribinirubi port pyrrolidone (PVP), polyvinyl alcohol (PVA), methylcellulose, E chill cellulose, hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), dextrin, maltodextrin dextrin, lactose, D- Man - tall, poly Bulle alcohol polymer one can mention methacrylic acid copolymer, aminoalkyl methacrylate copolymers and acrylic acid E Chi le 'methacrylate copolymer and the like.

[0011] if necessary, in the coating composition, the amount of plasticizer used generally excipients, lubricants, masking agents, one or more additives such as coloring agents and preservatives it can be included.

[0012] Types of plasticizers which may be used in the present invention is not particularly limited, those skilled in the art can be selected appropriately. Such plasticizers include, for example, macrogol 6000, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin and sorbitol, glycerin triacetate, phthalic acid Jechiru and Taen acid triethyl, lauric acid, sucrose, de Kisutorosu, Sonorebitonore, Toriasechin, § cetirizine Honoré tri E Chino les Tito rate, Toryechinorechi traits, tributyl Tito rate, can be cited § cetyl tributyl Chi Torre one bets like.

[0013] Excipients that may be used in the present invention, for example, lactose, Man - Thor, crystalline cellulose, dextrose, may be mentioned maltodextrins, and the like.

[0014] Lubricants that can be used in the present invention, for example, talc, magnesium stearate, stearate calcium, stearic acid.

[0015] Examples of the masking agent that can be used in the present invention, for example, a Sani匕 titanium.

[0016] As the colorant usable in the present invention, for example, titanium oxide, iron oxide, iron sesquioxide, yellow iron sesquioxide, yellow No. 5 aluminum lake talc.

[0017] Preservatives that can be used in the present invention, for example, a Bruno Ben like.

[0018] In the present invention, the active ingredients contained in the film coating formulation, its structure as long as the drug having an odor, but is not limited by the degree or the like, preferably olmesartan medoxomil or 2-Amino - 5 - isobutyl -4- {2- [5- (Ν, Ν'- bis ((S)-l-E Tokishikarubo - Le) Echiru) phosphonamido] hula - Le} thiazole, particularly preferably O Rumesarutan it is medoxomil. Incidentally, olmesartan medoxomil, the disease (more specifically derived from hypertension or high blood pressure, hypertension, heart disease [angina pectoris, myocardial infarction, arrhythmias, heart failure or cardiac hypertrophy], kidney diseases [diabetic nephropathy diseases, glomerular nephritis or nephrosclerosis], or cerebrovascular disease [cerebral infarction or cerebral hemorrhage]) is effective for the prevention or treatment of

, Follow the method described in Japanese Patent No. 2082519 (U.S. Patent No. 5, 616, 599 JP), etc., it can be easily produced. Also, 2-Amino - 5-isobutyl -4- {2- [5- (Ν, Ν'- bis ((S)-l-ethoxycarbonyl - Le) Echiru) phosphonamido] Hula - Le} thiazole, diabetes , hyperglycemia, impaired glucose tolerance, obesity, is effective for the prevention or treatment of such diabetic complications (preferably prevention or treatment of diabetes), according to the method described in WO 01Z47935 pamphlet or the like, easily it can be produced.

[0019] The film coating formulations of the present invention may also contain other active Ingredients when necessary. Examples of the active ingredient, for example, trichlormethiazide (Trichlor omethiazide), Hidorokuro port thiazide (Hydrochlorothiazide ^ benzylidene Honoré hydrochloride port Chiaji de (Benzylhydrochlorothiazide), diuretics such as; Azeru - adipic (Azelnidipine), Am Rojipin (amlodipine ), base - adipic (Benidipine), - Torenjipin (Nitrendipine), Ma - di pin (Manidipine), - Karujipin (Nicardipine), two Fuejipin (Nifedipine), sill - adipic (Cilnidipine), Eho - adipic (Efonidipine), Bruno Le - adipic (Barnidipine), Fuerojipin calcium antagonists such as (Fel odipine); pioglitazone (pioglitazone), rosiglitazone (Rosigl itazone), rivoglitazone (rivoglitazone), MCC- 555, NN- 2344, BMS- 298585, AZ - 242, LY- 519818, TAK- insulin sensitizer such as 559; pravastatin (pravastatin), sympathizers statins (Simvastatin), atorvastatin Such as SMP- 797, pactimibe (Pactimibe); (Atorvastatin), Rosupasutachin (Rosu vastatin), cerivastatin (Cerivastatin), Pitapa statin (Pitavastatin), HMG- CoA reductase inhibitors such as full pasta Chin (fluvastatin) force and the like ACAT inhibitor is not limited thereto. the amount of these active ingredients may be used the amount used in the normal formulation Nag limited in particular.

[0020] As film-coated preparation of the present invention, for example, tablets, capsules, dispersion, fine granules, granules, and the like can be illustrated troches, preferably a tablet.

[0021] As a method for producing a film-coated preparation of the present invention, Powder Technology and Pharmaceutical Processes (D. Chulia et general methods described in publications such as Elsevier Science Pub Co (December 1, 1993 " Yogu special restrictions are not provided if prepared using.

[0022] Film coating formulations prepared by this method may be obtained by spraying a film coating solution containing carboxymethyl cellulose sodium as a coating base, a tablet, the object to be coated, such as drug can.該被 object to be overturned may be subcoating desired. The film coating liquid suspending the additives to be blended with sodium carboxy methyl cellulose and optionally in water, obtained by dissolve. Spraying of the film coating solution may be performed by a known method such as are use a commercially available film coating machine. These production conditions may be adopted conditions in the production of conventional film Coated ring formulation.

[0023] The amount of film coating is not particularly limited as Re quantity der that can be effectively reduced odor with drugs, usually lower l% relative formulation weight (w / w) or more, preferably 3% (w / w) or more, more preferably at 6% (w / w) or more, 50% upper limit for the formulation weight (w / w) or less, preferably 20% (w / w) or less, more preferably it is carried out as a 10% (w / w) or less.

[0024] The film thickness of the film layer is not particularly limited as long as a thickness that can be effectively reduced odor with drug, usually the lower limit is more than 1 m, preferably 5 m (16.4 feet) or more, more preferably 10 m or more , particularly preferably 20 mu m or more, and the upper limit is less 1000 mu m, preferably less 500 mu m, further preferably not more than 200 mu m, particularly preferably not more than 100 mu m.

[0025] The film thickness of the film layer can be measured by an ultra-deep color 3D profile measuring microscope VK-9500 ((Ltd.) Keyence).

[0026] Kakaku film coated preparation of the present invention obtained may be administered as usual formulations.

[0027]

Example

[0028] Hereinafter, the present invention is described in further detail by examples etc., but the present invention is not shall be limited thereto.

(Example 1) olmesartan medoxomil 300 g, lactose 1850 g, hydroxypropyl methylcellulose 60 g, croscarmellose sodium 175g of high-speed stirring granulator (VG-10, Baurekku) After mixing, granulating said by adding purified water 500g at and dried in a fluidized bed dryer (Baurekku). Was sized granules at granulator (Comil, Bruno Urekku), magnesium stearate 15g with mixer (V-blender, Tokuju Seisakusho) were mixed in. The resulting mixture was die 7mm diameter by rotary tableting machine (Chrysanthemum water Seisakusho) at R Menkine radius of curvature 8 mm, to obtain Seijo, plain tablets such that per tablet weight 160 mg.

[0029] To the obtained plain tablets 1000 g, using a coating solution obtained by dissolving sodium carboxymethylcellulose 100g of purified water 1900 g, the coating machine (Doriako one coater the DRC-300, Paure click) at, relative to uncoated tablets weight Te 6% by (w / w) coating, to obtain a film-coated tablets (a).

[0030]

(Comparative Example 1)

A plain tablet 1000g obtained in Example 1, hydroxypropylmethylcellulose 140 g, talc 30g, the use of a coating solution suspended in purified water 1800g titanium oxide 30g, coating machine (Doriako one coater the DRC-300, Roh Urekku) at 6% relative to uncoated weight (w / w) and Kotin grayed to give film-coated tablets (B).

[0031]

(Test Example 1)

Glass bottle, uncoated tablets and film-coated tablets produced in Example 1 (A), placed in a film-coated tablet (B) each 30 tablets prepared in Comparative Example 1 was stored for 3 hours at 40 ° C. Open this glass bottle, it was carried out a functional test of the smell in the following evaluation criteria by the five subjects. The results are shown in Table 1.

[0032]

(Sensory Evaluation Criteria)

<Score> <content>

0: smell not

1: slightly smell 2: smell

3: Pretty smell

(Table 1) of the tablet odor evaluation

(Example 2)

A plain tablet lOOOg obtained in Example 1, dextrose 30g, carboxymethyl using a coating solution obtained by dissolving in purified water 1900g methyl cellulose sodium 70 g, coating machine (drill aquo one coater DRC-300, Paurekku) at, uncoated tablets and 6% (w / w) coating by weight, to obtain a full Ilm coated tablets (c).

[0033]

(Comparative Example 2)

A plain tablet lOOOg obtained in Example 1, hydroxypropylmethylcellulose 140 g, talc 30g, using a coating liquid suspended in purified water 1800g titanium oxide 30g, coating machine (Doriako one coater the DRC-300, Paurekku) to Te, 6% relative to the uncoated tablet weight (w / w) and Kotin grayed to give film-coated tablets (D).

[0034]

(Test Example 2)

Glass bottle, uncoated tablets prepared in Example 1, film-coated tablets produced in Example 2 (C), the film-coated tablet (D) each 30 tablets prepared in Comparative Example 2 was placed, 40. For 3 hours saved in C. Open this glass bottle was a sensory test of odor by the following evaluation criteria by five subjects. The results are shown in Table 2.

(Sensory Evaluation Criteria)

<Score> <content>

0: smell not

1: Slightly smell

2: smell

3: Pretty smell

Evaluation (Table 2) of the tablets smell

Industrial Applicability

According to the present invention, substantially above odor! /, It's! / ,, goods excellent in film coating formulation is obtained.

Claims

The scope of the claims
[1] contains olmesartan medoxomil in the formulation, film coating formulation containing carboxymethyl cellulose sodium film layer.
[2] olmesartan medoxomil containing mills and other agents at the same time, a film coating formulation containing a force Lupo carboxymethylcellulose sodium in the film layer in the formulation.
[3] in the formulation of 2-Amino - 5-isobutyl -4- {2- [5- (Ν, Ν'- bis ((S)-l-ethoxycarbonyl - Le) E chill) phosphonamido] Hula - Le } contains thiazole, film co one coating formulation containing carboxymethyl cellulose sodium © beam to the film layer.
[4] the film layer, the film coating formulation according to any of claims 1 to 3 is a coating composition further contains a coating base or excipient.
[5] coating base or excipient force hydroxymethyl cellulose, hydro hydroxypropyl cellulose, polyvinyl pyrrolidone, polyvinyl alcohol, Mechiruseru port over scan, E chill cellulose, dextrin, maltodextrin, lactose, D- Man - Tall, port polyvinyl alcohol polymers, methacrylic acid copolymers, aminoalkyl methacrylate copolyarylene Rimmer and film coating formulation of claim 4 is one or more of methyl acrylate Echiru 'methacrylate copolymer force chosen compound.
[6] coating base or excipient, Fuinoremuko one coating formulation of claim 5 which is a maltodextrin or dextrin.
[7] the film layer, fill beam coating formulation according to any one of claims 1 to 6 further contains a plasticizer.
[8] plasticizer, macrogol 6000, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin and sorbitol, glycerin triacetate, phthalic acid Jechiru and Taen acid triethyl, lauric acid, sucrose, dextrose, sorbitol, Toriasechin, Asechi Norre tri E Chino les Tito, tri E Chino les Tito rate, tributyrate Honoré Tito rate, Fuinoremuko one coating formulation according to claim 7 is one or more compounds selected from § cetyl tributyl Tito rate.
[9] plasticizer, a film coating formulation of claim 7 dextrose.
[10] plasticizer, a film coating formulation of claim 8 wherein Toriasechin.
[11] formulation, film coating formulation according to any 〖this claim 1 to 10 is a tablet.
[12] Film layer forces l% relative formulation weight (w / w) or more in film coating formulation according to any of claims 1 to 11.
[13] Film layer strength 3% relative formulation weight (w / w) or more in film coating formulation according to any of claims 1 to 11.
[14] Film-coated formulation according to any of claims 1 to 11 film layer is of thickness force 1 mu m or more.
[15] Fill uncoated formulation according to any of claims 1 to 11 film layer is of thickness force 20 m or more.
PCT/JP2006/309993 2005-05-20 2006-05-19 Film coated preparation WO2006123765A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2005147436 2005-05-20
JP2005-147436 2005-05-20

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20077026731A KR101318032B1 (en) 2005-05-20 2006-05-19 Film coated preparation
JP2007516344A JP5000491B2 (en) 2005-05-20 2006-05-19 Film coating formulation
CN 200680015726 CN101171006B (en) 2005-05-20 2006-05-19 Film coated preparation

Publications (1)

Publication Number Publication Date
WO2006123765A1 true true WO2006123765A1 (en) 2006-11-23

Family

ID=37431333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/309993 WO2006123765A1 (en) 2005-05-20 2006-05-19 Film coated preparation

Country Status (4)

Country Link
JP (1) JP5000491B2 (en)
KR (1) KR101318032B1 (en)
CN (1) CN101171006B (en)
WO (1) WO2006123765A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008050714A1 (en) * 2006-10-25 2008-05-02 Daiichi Sankyo Company, Limited Packaging material
WO2008078728A1 (en) * 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited Ascorbic acid-containing pharmaceutical composition
WO2008078727A1 (en) * 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved dissolution property
WO2009057569A1 (en) * 2007-10-29 2009-05-07 Daiichi Sankyo Company, Limited Film-coated preparation
WO2010018777A1 (en) * 2008-08-11 2010-02-18 第一三共株式会社 Odor-controlling method
JPWO2008069262A1 (en) * 2006-12-07 2010-03-25 第一三共株式会社 Improved stability film coating formulation
CN102028663A (en) * 2010-12-14 2011-04-27 北京万生药业有限责任公司 Stable olmesartan medoxomil solid preparation
JP2011195567A (en) * 2010-02-26 2011-10-06 Daiichi Sankyo Co Ltd tablet
WO2012029820A1 (en) 2010-08-31 2012-03-08 東レ株式会社 Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation
JP2014517046A (en) * 2011-06-24 2014-07-17 アセンダ ファーマ インコーポレイテッド The methods and improved pharmaceutical compositions for improving the absorption of ester prodrug
WO2014188728A1 (en) * 2013-05-24 2014-11-27 持田製薬株式会社 Film-coating composition
JP2016044170A (en) * 2014-08-27 2016-04-04 日本ケミファ株式会社 Olmesartan prodrug formulation
JP2017001999A (en) * 2015-06-12 2017-01-05 富士フイルム株式会社 Manufacturing method of medicine-containing particles, medicine-containing particles, pharmaceutical composition, and orally disintegrating tablet

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003051973A (en) * 2001-08-07 2003-02-21 Hitachi Maxell Ltd Camera module
JP2003048852A (en) * 2000-11-21 2003-02-21 Sankyo Co Ltd Medical composition
WO2004067003A1 (en) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
JP2005162619A (en) * 2003-11-28 2005-06-23 Ss Pharmaceut Co Ltd Evaporation preventing type solid pharmaceutical preparation and method for producing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
CA2322293A1 (en) * 1998-12-31 2000-07-13 Hercules Incorporated Hydroxypropylcellulose and anionic polymer compositions and their use as pharmaceutical film coatings
CA2396713A1 (en) * 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
US6419956B1 (en) 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
KR100656716B1 (en) 2000-11-21 2006-12-13 상꾜 가부시키가이샤 Medicinal compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048852A (en) * 2000-11-21 2003-02-21 Sankyo Co Ltd Medical composition
JP2003051973A (en) * 2001-08-07 2003-02-21 Hitachi Maxell Ltd Camera module
WO2004067003A1 (en) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
JP2005162619A (en) * 2003-11-28 2005-06-23 Ss Pharmaceut Co Ltd Evaporation preventing type solid pharmaceutical preparation and method for producing the same

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008050714A1 (en) * 2006-10-25 2008-05-02 Daiichi Sankyo Company, Limited Packaging material
JPWO2008069262A1 (en) * 2006-12-07 2010-03-25 第一三共株式会社 Improved stability film coating formulation
WO2008078728A1 (en) * 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited Ascorbic acid-containing pharmaceutical composition
WO2008078727A1 (en) * 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved dissolution property
JP5241511B2 (en) * 2006-12-26 2013-07-17 第一三共株式会社 Elution of improved pharmaceutical compositions
JPWO2009057569A1 (en) * 2007-10-29 2011-03-10 第一三共株式会社 Film coating formulation
WO2009057569A1 (en) * 2007-10-29 2009-05-07 Daiichi Sankyo Company, Limited Film-coated preparation
JP2015017136A (en) * 2008-08-11 2015-01-29 第一三共株式会社 Method for decreasing odor
WO2010018777A1 (en) * 2008-08-11 2010-02-18 第一三共株式会社 Odor-controlling method
JP5688799B2 (en) * 2008-08-11 2015-03-25 第一三共株式会社 Odor suppression method
JP2011195567A (en) * 2010-02-26 2011-10-06 Daiichi Sankyo Co Ltd tablet
US9381248B2 (en) 2010-08-31 2016-07-05 Toray Industries, Inc. Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation
WO2012029820A1 (en) 2010-08-31 2012-03-08 東レ株式会社 Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation
CN102028663A (en) * 2010-12-14 2011-04-27 北京万生药业有限责任公司 Stable olmesartan medoxomil solid preparation
JP2014517046A (en) * 2011-06-24 2014-07-17 アセンダ ファーマ インコーポレイテッド The methods and improved pharmaceutical compositions for improving the absorption of ester prodrug
WO2014188728A1 (en) * 2013-05-24 2014-11-27 持田製薬株式会社 Film-coating composition
JP2016044170A (en) * 2014-08-27 2016-04-04 日本ケミファ株式会社 Olmesartan prodrug formulation
JP2017001999A (en) * 2015-06-12 2017-01-05 富士フイルム株式会社 Manufacturing method of medicine-containing particles, medicine-containing particles, pharmaceutical composition, and orally disintegrating tablet

Also Published As

Publication number Publication date Type
CN101171006A (en) 2008-04-30 application
KR101318032B1 (en) 2013-10-14 grant
KR20080011394A (en) 2008-02-04 application
JPWO2006123765A1 (en) 2008-12-25 application
JP5000491B2 (en) 2012-08-15 grant
CN101171006B (en) 2010-12-01 grant

Similar Documents

Publication Publication Date Title
US20050186274A1 (en) Multilayer tablet
US20060018960A1 (en) Galenic formulations of organic compounds
US20060057202A1 (en) Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
WO2011138380A1 (en) Pharmaceutical formulations comprising pioglitazone and linagliptin
WO2007017423A2 (en) Pharmaceutical composition comprising a dpp-iv inhibitor
WO2007041053A2 (en) Formulation comprising metformin and vildagli ptin
WO2006135723A2 (en) Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US20040235850A1 (en) Pharmaceutical compositions of varenicline
WO2005117841A1 (en) Coated tablet formulation and method
US20030180360A1 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene
WO2003090720A1 (en) High drug load tablet
WO2006070248A1 (en) Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
WO2013179307A2 (en) Stabilized pharmaceutical compositions of saxagliptin
WO2007031933A2 (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2015086467A1 (en) Pharmaceutical compositions comprising dimethyl fumarate
WO2010017432A1 (en) Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US20060083785A1 (en) Large dose ribavirin formulations
US20090143404A1 (en) Pharmaceutical composition
WO2008032107A1 (en) Solid dosage form of olmesartan medoxomil and amlodipine
US20060078615A1 (en) Bilayer tablet of telmisartan and simvastatin
WO2010060564A1 (en) Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin-ii antagonist and/or a diuretic
JPH09143073A (en) Prolonged action nifedipine preparation
WO2008020820A2 (en) Pharmaceutical compositions comprising aripiprazole
WO2009084036A2 (en) Composition for treatment of viral infections
WO2009118359A2 (en) Capsule for the prevention of cardiovascular diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007516344

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct app. not ent. europ. phase

Ref document number: 06746649

Country of ref document: EP

Kind code of ref document: A1